Client Result
Orrick Advises Bayer on Partnership with Ginkgo Bioworks
October.17.2022

October.17.2022
September.19.2022
August.09.2022
June.27.2022
The primary focus of the acquisition is on the lead medicine, Tazverik® (tazemetostat), a first-in-class, chemotherapy-free EZH2a inhibitor.
June.06.2022
May.31.2022
April.27.2022
April.13.2022
December.22.2021
December.20.2021
October.20.2021
Orrick has advised Turn/River Capital on its investment in Invicti Security’s $625 million funding round, led by Summit Partners.
September.24.2021